HepaRegeniX Closes €21.5M in Funding
Summary
HepaRegeniX GmbH, a Tuebingen, Germany-based clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, raised €21.5M in funding. Led by CEO Elias Papatheodorou, HepaRegeniX develops therapies to treat acute and chronic liver diseases based on discoveries of a novel cellular target and small molecules that enable the liver to regenerate rapidly. Building on demonstrated safety in clinical trials, it is progressing HRX-215 to prevent post-hepatectomy liver failure, facilitate transplantation of smaller living donor liver grafts, and treat severe alcohol-associated hepatitis. Beyond liver diseases, the company is also developing HRX-233 to target kinase inhibitor treatment resistance in KRAS-driven tumors. HepaRegeniX is backed by life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion GmbH and Wellington Partners.